Ipsen: Q3 sales up 2.2% at constant FX

(CercleFinance.com) - Ipsen has reported Q3 2020 sales growth of 2.
2% at constant exchange rates (-1.8% as reported to 633.3 million euros), driven by 5.1% growth in specialty medicine, despite the continued impact of Covid-19.

The sound performance in the third quarter thus enabled the pharmaceutical company to record YTD sales growth of 2.8% at constant exchange rates (reported sales up 1.5%).

Ipsen confirms its 2020 targets, including sales growth of over 2% at constant exchange rates, with an expected unfavourable currency impact of around 1.5%, and an operating margin of activities exceeding 30%.


Copyright (c) 2020 CercleFinance.com. All rights reserved.